Confident Biomarker Decisions Start Here
Biomarkers help de-risk studies, guide decisions, and enable precision medicine. Without the right planning, milestones slip, confidence and funding fades, and even worse, patients miss out on potentially life-saving treatments. Finding the right partner early helps you select the right platform, navigate the regulatory landscape, and identify and secure services across the drug development lifecycle.
Many biomarker programs fail to deliver value — not because of the science, but because of misalignment between assay performance and its context of use. Many companies often miss these hidden pitfalls:
- Unclear, or lack of, cohesive biomarker strategy
- Failure to evolve for real-world applications
- Delayed results due to complex sample logistics
- Fragmented vendor execution with no unified data strategy
Biomarkers aren’t a tactical checkbox — they’re a strategic lever. Used correctly, they de-risk development, enable informed decision making, and increase your odds of clinical and commercial success. From discovery to the clinic, you can accelerate your development with strategy-first biomarker support.
A Smarter Path from Biomarker Discovery to Clinical Execution
Biomarkers are no longer just supporting data — they’re shaping study design, driving discovery up to the clinical decisions, and defining regulatory outcomes. Modern biomarker solutions start with the end in mind. They build biomarker strategies in parallel with drug development. They plan for scale, translation, and submission from the start, using a single trusted partner to handle everything.
Charles River brings your biomarker vision to life with one aligned strategy. From exploratory discovery to clinical validation, we partner early to identify the right biomarkers for your endpoints, therapeutic context, and regulatory path. We then carry that strategy forward with the infrastructure to execute globally and the expertise to adapt along the way.
How We Deliver Smarter Biomarker Execution
With over 75 years of experience and over 2,000 scientists, we don’t just execute biomarker programs — we elevate them. Our integrated, expert-driven biomarker partnership provides:
- A one-stop shop for all biomarker needs from early discovery to clinical validation
- Platform-agnostic recommendations for methods that scale and validate globally
- Integrated scientific advisory services, not just technicians running tests
- Multi-omic flexibility (flow cytometry, genomics, proteomics, imaging, and more)
- Real-time access to data with Charles River’s Apollo™, so you’re never waiting on results
- Regulatory insight embedded into the process from start to finish to ensure data is fit for purpose and ready for submission
Take the Guesswork Out of Biomarkers
We have supported the discovery of over 100 preclinical candidates in the last 10 years, of which 33% reached clinical proof of concept. Charles River also supports thousands of molecules annually, handles over 5,000 biomarkers annually, and continuously evolves our platforms to meet the demands of complex, global studies.
Whether you’re evaluating early candidates or finalizing your clinical strategy, it’s never too early, or too late, to make the right biomarker decisions to:
- Design with confidence from day one
- Gain a true partner who integrates science, strategy, and execution
- Improve the probability of success of your drug candidate by collaborating with us